High interindividual variability in plasma clopidogrel active metabolite concentrations in healthy cats is associated with sex and cytochrome P450 2C genetic polymorphism

被引:10
作者
Lee, Pamela M. [1 ]
Faus, Michele C. L. [1 ]
Court, Michael H. [1 ]
机构
[1] Washington State Univ, Coll Vet Med, Dept Vet Clin Sci, Program Individualized Med PrlMe, Pullman, WA 99164 USA
关键词
antiplatelet; antithrombotic; Plavix; thienopyridine; thromboprophylaxis; TREATMENT PLATELET REACTIVITY; CARBOXYLIC-ACID METABOLITE; HPLC-MS/MS METHOD; THIOL METABOLITE; BLEEDING EVENTS; PHARMACOKINETICS; AGGREGATION; ASPIRIN; IMPACT;
D O I
10.1111/jvp.12717
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Clopidogrel response variability has been identified in cats. In humans, evidence suggests that variable clopidogrel active metabolite (CAM) generation is the primary explanation for clopidogrel response variability with differences in body weight, sex, and variable metabolism of clopidogrel primarily due to polymorphisms of the gene encoding cytochrome P450 (CYP) 2C19 as some proposed mechanisms. The aim of this study was to evaluate whether variation in CAM concentrations exists in healthy cats and what the cause of such variation might be. Nineteen healthy cats were given 18.75 mg clopidogrel by mouth. Blood was collected 2 hr later. Plasma CAM concentrations were measured using high performance liquid chromatography and tandem mass spectrometry. Clopidogrel metabolism was estimated by calculating CAM metabolic ratio. DNA was collected, and feline CYP2C genotyping was performed. The cats demonstrated high interindividual variation of plasma CAM concentrations. Approximately 69% of this interindividual variation was primarily explained by differences in clopidogrel metabolism as measured by CAM metabolic ratio with some influence by sex but not by weight. A single nucleotide polymorphism was identified in the feline CYP2C gene that explained in part individual differences in CAM metabolic ratio and CAM plasma concentrations.
引用
收藏
页码:16 / 25
页数:10
相关论文
共 25 条
[1]   Genome-wide analysis of clopidogrel active metabolite levels identifies novel variants that influence antiplatelet response [J].
Backman, Joshua D. ;
O'Connell, Jeffrey R. ;
Tanner, Keith ;
Peer, Cody J. ;
Figg, William D. ;
Spencer, Shawn D. ;
Mitchell, Braxton D. ;
Shuldiner, Alan R. ;
Yerges-Armstrong, Laura M. ;
Horenstein, Richard B. ;
Lewis, Joshua P. .
PHARMACOGENETICS AND GENOMICS, 2017, 27 (04) :159-163
[2]   Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate [J].
Bonello, Laurent ;
Tantry, Udaya S. ;
Marcucci, Rossella ;
Blindt, Ruediger ;
Angiolillo, Dominick J. ;
Becker, Richard ;
Bhatt, Deepak L. ;
Cattaneo, Marco ;
Collet, Jean Philippe ;
Cuisset, Thomas ;
Gachet, Christian ;
Montalescot, Gilles ;
Jennings, Lisa K. ;
Kereiakes, Dean ;
Sibbing, Dirk ;
Trenk, Dietmar ;
Van Werkum, Jochem W. ;
Paganelli, Franck ;
Price, Matthew J. ;
Waksman, Ron ;
Gurbel, Paul A. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 56 (12) :919-933
[3]   Pharmacodynamic and pharmacokinetic evaluation of clopidogrel and the carboxylic acid metabolite SR 26334 in healthy dogs [J].
Brainard, Benjamin M. ;
Kleine, Stephanie A. ;
Papich, Mark G. ;
Budsberg, Steven C. .
AMERICAN JOURNAL OF VETERINARY RESEARCH, 2010, 71 (07) :822-830
[4]   New P2Y12 Inhibitors [J].
Cattaneo, Marco .
CIRCULATION, 2010, 121 (01) :171-179
[5]   The influence of CYP2C19*2 and*17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting [J].
Harmsze, Ankie M. ;
van Werkum, Jochem W. ;
Hackeng, Christian M. ;
Ruven, Hendrik J. T. ;
Kelder, Johannes C. ;
Bouman, Heleen J. ;
Breet, Nicoline J. ;
ten Berg, Jurrien M. ;
Klungel, Olaf H. ;
de Boer, Anthonius ;
Deneer, Vera H. M. .
PHARMACOGENETICS AND GENOMICS, 2012, 22 (03) :169-175
[6]   Impact of Genetic Polymorphisms in CYP2C9 and CYP2C19 on the Pharmacokinetics of Clinically Used Drugs [J].
Hirota, Takeshi ;
Eguchi, Shunsuke ;
Ieiri, Ichiro .
DRUG METABOLISM AND PHARMACOKINETICS, 2013, 28 (01) :28-37
[7]   Secondary prevention of cardiogenic arterial thromboembolism in the cat: the double-blind, randomized, positive-controlled feline arterial thromboembolism; clopidogrel vs. aspirin trial (FAT CAT) [J].
Hogan, Daniel F. ;
Fox, Philip R. ;
Jacob, Kristin ;
Keene, Bruce ;
Laste, Nancy J. ;
Rosenthal, Steven ;
Sederquist, Kimberly ;
Weng, Hsin-Yi .
JOURNAL OF VETERINARY CARDIOLOGY, 2015, 17 :S306-S317
[8]   Antiplatelet effects and pharmacodynamics of clopidogrel in cats [J].
Hogan, DF ;
Andrews, DA ;
Green, HW ;
Talbott, KK ;
Ward, MP ;
Calloway, BM .
JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, 2004, 225 (09) :1406-1411
[9]   Impact of CYP3A5 polymorphism on platelet reactivity at percutaneous coronary intervention and after 9 months of aspirin and clopidogrel therapy in Japanese patients with coronary artery disease [J].
Hokimoto, Seiji ;
Chitose, Tadasuke ;
Mizobe, Michio ;
Akasaka, Tomonori ;
Arima, Yuichiro ;
Kaikita, Koichi ;
Iwashita, Satomi ;
Morita, Kazunori ;
Miyazaki, Hiroko ;
Oniki, Kentaro ;
Matsui, Kunihiko ;
Nakagawa, Kazuko ;
Ogawa, Hisao .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 70 (06) :667-673
[10]   Cytochrorne P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects [J].
Hulot, Jean-Sebastien ;
Bura, Alessandra ;
Villard, Eric ;
Azizi, Michel ;
Remones, Veronique ;
Goyenvalle, Catherine ;
Aiach, Martine ;
Lechat, Philippe ;
Gaussem, Pascale .
BLOOD, 2006, 108 (07) :2244-2247